Best Buy Stocks -

: Up over 267% YTD after reporting positive clinical data for its RAS/MAPK pathway-driven cancer treatments.

: Up over 204% YTD following successful Phase 3 trials for its psoriasis therapy. best buy stocks

: Up over 115% YTD (as of April 27) following a recent 21% surge and bullish outlook on its manufacturing turnaround. Analyst "Best Buy" Recommendations for 2026 : Up over 267% YTD after reporting positive

Several companies have seen triple-digit gains in the first four months of 2026, often led by specialized healthcare breakthroughs or critical AI hardware components. best buy stocks